Corbus Pharmaceuticals Holdings

CRBP · NASDAQ

$4.42−$0.04 (−0.90%)TodayMarket closed ·
Prev close $4.46

Latest news

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

  • NewsVandana Singh

    Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'

  • News

    Market-Moving News for September 14th

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

  • News

    12 Health Care Stocks Moving In Friday's After-Market Session

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

  • News

    12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

  • News

    Corbus Pharmaceuticals Q4 Earnings Summary & Key Takeaways

  • Press releaseGlobe Newswire

    Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

  • News

    12 Health Care Stocks Moving In Friday's Intraday Session

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • NewsAvi Kapoor

    Roku, SPS Commerce, Newell Brands And Other Big Stocks Moving Lower In Friday's Pre-Market Session

  • NewsAvi Kapoor

    Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket

  • News

    12 Health Care Stocks Moving In Thursday's After-Market Session

  • NewsNicolás Jose Rodriguez

    Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

  • NewsAvi Kapoor

    Crude Oil Moves Higher; Sable Offshore Shares Slide

  • NewsAvi Kapoor

    Gold Gains Over 1%; Battalion Oil Shares Spike Higher

  • NewsRolando García

    Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints

  • NewsNicolás Jose Rodriguez

    Cannabis Stocks React To Trump's Marijuana Comments: See Which Ones Posted Solid Gains

  • News

    10 Health Care Stocks Whale Activity In Today's Session

  • NewsMichael Juliano

    GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing (CORRECTED)

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.